
Insight Molecular Diagnostics Inc.: updates and filings
Price
$1.97
November 20, 2026Market cap $63M
What Ploutos Investor adds for Insight Molecular Diagnostics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 16, 2026next Feb 11, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
September 2026
August 2026
May 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 18, 2026Material agreement entered, other material eventsForm8-K
- Nov 16, 2026Results of operationsForm8-K
- Nov 16, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Sep 21, 2026Material agreement enteredForm8-K
- Aug 10, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 10, 2026Results of operations, Regulation FD disclosure, other material eventsForm8-K
- Jul 24, 2026Shares registered for employeesFormS-8
- Jun 17, 2026Officer or director change, shareholder voteForm8-K
- May 13, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 13, 2026Results of operationsForm8-K
- May 13, 2026Other material events (amendment)Form8-K/A
- Apr 30, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 30, 2026Additional annual meeting materialFormDEFA14A
- Apr 30, 2026Annual meeting proxy statementFormDEF 14A
- Apr 30, 2026Other material eventsForm8-K
- Apr 27, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Mar 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 26, 2026Results of operationsForm8-K
- Feb 26, 2026Material agreement enteredForm8-K
- Feb 12, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Feb 12, 2026Material agreement entered, other material eventsForm8-K
- Feb 11, 2026Regulation FD disclosureForm8-K
- Nov 10, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Nov 10, 2025Results of operationsForm8-K
- Oct 2, 2025Officer or director changeForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 18, 2026 | 8-K | Material agreement entered, other material events | Document |
| Nov 16, 2026 | 8-K | Results of operations | Document |
| Nov 16, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Sep 21, 2026 | 8-K | Material agreement entered | Document |
| Aug 10, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 10, 2026 | 8-K | Results of operations, Regulation FD disclosure, other material events | Document |
| Jul 24, 2026 | S-8 | Shares registered for employees | Document |
| Jun 17, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 13, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 13, 2026 | 8-K | Results of operations | Document |
| May 13, 2026 | 8-K/A | Other material events (amendment) | Document |
| Apr 30, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 30, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 30, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 30, 2026 | 8-K | Other material events | Document |
| Apr 27, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Mar 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 26, 2026 | 8-K | Results of operations | Document |
| Feb 26, 2026 | 8-K | Material agreement entered | Document |
| Feb 12, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Feb 12, 2026 | 8-K | Material agreement entered, other material events | Document |
| Feb 11, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 10, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Nov 10, 2025 | 8-K | Results of operations | Document |
| Oct 2, 2025 | 8-K | Officer or director change | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 14, 2015.
The full analysis
What do Insight Molecular Diagnostics's filings show?
The filings are where every one of Insight Molecular Diagnostics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.